J.P. Morgan42nd Healthcare Conference Prahlad Singh Chief Executive Officer January 9, 2024

Safe Harbor This presentation contains "forward-looking" statements which are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation. Guidance for future periods is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company’s results prepared in accordance with GAAP. 2

Revolutionizing human health at an accelerated [rev] speed Embracing the impossible to improve lives [vita] Revvity is a company which powers new possibilities for the future of human health 3 3

Our company profile: global scale with differentiated positioning Consumables, Services, Software ~80% Instruments ~20% Diagnostics Life Sciences 2023E Non-Covid Revenue Mix ~44% AMERICAS ~27% EMEA ~29% APAC 4 ~47% ~53% ~$2.7B Expanding the boundaries of human potential through science Note: Based on guidance provided October 30, 2023

Reagents (antibodies, oligos) for biomarker analysis Flow-based assays Cell and gene therapy Single-cell applications Pre-clinical imaging Cellular analysis Detection instrumentation Pioneering innovation to propel our life sciences customers’ R&D efforts Robust solutions, through our Revvity Signals platform, for research and clinical informatics $0.4B Instruments Life Sciences at-a-glance 5 ~$1.3B 2023E Revenue $20B+ Total Addressable Market $0.7B Reagents, Assays, & Services $0.2B Software Select brands and products Oligos Flow Cytometry In Vivo Imaging High-Content Screening Automated Cell Counter Note: Based on guidance provided October 30, 2023 Viral Vectors & Genetic Material

Diagnostics at-a-glance 6 ~$1.4B 2023E Revenue $35B+ Total Addressable Market Leading franchises dedicated to advancing human health Newborn screening Maternal and fetal health Cord-blood banking Global laboratory footprint Autoimmune Allergy Infectious disease (e.g., TB) Robust ‘omics sample prep portfolio Liquid handling Nucleic acid extraction $0.7B ImmunoDx $0.5B Reproductive Health $0.2B Applied Genomics Prenatal Screening Platform Newborn Screening System Auto-immune Assays Infectious Disease Assays Nucleic Acid Extraction Automated NGS Library Prep Maternal & Fetal Health Assays Note: Based on guidance provided October 30, 2023 Select brands and products NGS Assays

DISCOVER & DEVELOP DIAGNOSE Bringing it all together: powering innovation from Research to Reality 7 Screening Diagnostics Monitoring Helping scientists to discover more and translate faster Enabling labs to help physicians guide patient treatment Clinical Development Drug Discovery Basic Research Providing leading capabilities that facilitate decision making between research and clinical customers

Revvity’s Differentiation 8

Differentiating through our… 9 Positioning Approach Products

Pre-clinical innovation Global genomic labs Cutting-edge clinical diagnostics GMP manufacturing Our approach: serving our customers as a strategic partner 10 Strategic partner for… pin-point-base-editing-platform-presentation-v2.pdf (horizondiscovery.com) Multiple Customer Access Points Partnership Spotlight: PIN-POINTTM BASE EDITING TECHNOLOGY Products Licensing Services Launched reagents to enable technology evaluations and improve functional insights Pre-clinical Sep 2023 Clinical May 2023 Executed first clinical licensing agreement with AstraZeneca for oncology and immune-related diseases

Cutting-edge, high-value products which provide differentiated capabilities for customers Our products: specialized offerings that foster scientific innovation and positively impact human health 11 Product Spotlights Enhanced Imaging Portfolio Quantum GX3 microCT imaging solution Proteogenomics & Multiomics Reagents TotalSeqTM Automated Indirect Immunofluorescence Testing Automated Newborn Screening Workflow Scientific Data Management & Workflow Platform Research Platform Autoimmune Testing Menu UNIQO 160 EonisTM Q System

Our positioning: unique portfolio will continue to foster growth and drive attractive profitability profile 12 Strategic scientific partnerships with Pharma/Biotech across the Revvity portfolio to drive additional upside vs. underlying market growth 60% Strong recurring revenue mix with accretive margin profiles Cutting-edge scientific innovation drives strong competitive positioning ImmunoDx LS Reagents Software 9-11% 25% Differentiated, complementary pre-clinical platforms Complete NGS solutions LS Instrumentation Applied Genomics 3-5% 15% Cash flow generation to support continued investment Growth outperforming global birth rates Reproductive Health 2-4% % of Total ‘23E Revenue ($2.7B) Growth Profile Note: Based on guidance provided October 30, 2023 Portfolio Solutions Included Positioning

Current 2023E Guidance assumes +MSD organic growth in China Our positioning: unique revenue mix in China drives differentiated performance 13 $2.7B Total ‘23E Revenue China Our China exposure ~40% Life Sciences ~60% Diagnostics Strong recovery driven by ~70% of Dx revenue from specialized ImmunoDx (e.g., autoimmune, allergy, latent TB) and ~90% from consumables Recurring revenue now represents >50% of Life Sciences revenue, consisting of reagents and consumables Note: Based on guidance provided October 30, 2023

Looking Ahead 14

Key focus areas in 2024 Driving cross-company innovation & building on core growth accelerators Capturing cost efficiencies and commercial and operational synergies through sound execution Strategically deploying capital organically and inorganically INVESTMENT INNOVATION EFFICIENCY 15 Despite uncertain demand environments… …carrying momentum into Revvity’s 2nd year

Differentiated long-term outlook through economic cycles 16 Our outlook for 2025 and beyond: Organic Growth 200 bps above market normal market environment assumed to be 4-6% growth Operating Margin Expansion 75 bps / year Adj. EPS Growth DD growth Formal 2024 guidance to be provided on our upcoming 4Q23 earnings call